Screening for prostate cancer with PSA testing: current status and future directions.

Area of Science:

• Urology
• Oncology
• Medical Screening

Background:

• Serum prostate specific antigen (PSA) assay's role in prostate cancer screening is debated.
• Initially developed for treatment response evaluation, its widespread adoption for screening preceded robust evidence.
• Concerns exist regarding overdiagnosis and overtreatment associated with PSA testing.

Purpose of the Study:

• To review the literature on PSA testing for prostate cancer screening.
• To discuss explanations for contradictory results from major randomized trials.
• To reflect on the future of prostate cancer screening strategies.

Main Methods:

• Literature review of studies on PSA screening for prostate cancer.
• Analysis of observational data on overdiagnosis and overtreatment.
• Examination of interim results from randomized clinical trials on PSA screening efficacy.

Main Results:

• PSA testing's utility in reducing prostate cancer mortality is controversial.
• Observational data indicate significant overdiagnosis and overtreatment.
• Incongruent interim results from large randomized trials have intensified the debate.

Conclusions:

• The definitive impact of PSA screening on prostate cancer mortality requires further investigation.
• Understanding the reasons behind conflicting trial outcomes is crucial.
• Future prostate cancer screening strategies may need re-evaluation.